You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Express Scripts
Baxter
Colorcon
Moodys

Last Updated: September 18, 2020

DrugPatentWatch Database Preview

Patent: 6,653,113

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,653,113
Title: High efficiency gene targeting in mouse embryonic stem cells
Abstract:The present invention provides novel methods for modifying the genome of an animal cell which typically comprise the steps of: constructing a DNA molecule in which desired sequence modifications are contained in a segment of DNA (a \"targeting DNA\") that is substantially isogenic with a DNA in the cell genome (a \"target DNA\"); introducing the targeting DNA construct into the cell (e.g., by microinjection, electroporation, transfection, or calcium phosphate precipitation); and selecting cells in which the desired sequence modifications have been introduced into the genome via homologous recombination.
Inventor(s): Berns; Anton (Spaarndam, NL), Robanus Maandag; Els (Haarlem, NL), te Riele; Hein (Amsterdam, NL)
Assignee: Genpharm International, Inc. (Mountain View, CA)
Application Number:09/253,818
Patent Claims:see list of patent claims

Details for Patent 6,653,113

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Genpharm International, Inc. (Mountain View, CA) 2011-08-20 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Genpharm International, Inc. (Mountain View, CA) 2011-08-20 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Genpharm International, Inc. (Mountain View, CA) 2011-08-20 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
AstraZeneca
Express Scripts
McKinsey
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.